# RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

> **NCT06470061** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zaparackas and Knepper LTD** · enrollment: 200 (estimated)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment
- Cognitive Decline

## Interventions

- **DRUG:** Resveratrol, Quercetin, and Curcumin (RQC)
- **DRUG:** Curcumin

## Key facts

- **NCT ID:** NCT06470061
- **Lead sponsor:** Zaparackas and Knepper LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06470061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06470061, "RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06470061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*